Advancing Cancer Treatment
Therapeutics Discovery
Philip Jones, Ph.D.
Vice President
The Therapeutics Discovery division at MD Anderson was created to eliminate the bottlenecks that hamper traditional drug development.
Our team of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts develops small molecule drugs, biologics and cellular therapies, inspired by the needs of MD Anderson cancer patients and guided by the expertise of the center’s clinicians. To create life-saving transformational medicines quickly, safely and effectively, Therapeutics Discovery works with unparalleled proximity to patients and an unmatched wealth of clinical experience.
Therapeutics Discovery doesn’t bring the “bench to bedside” – it starts with the bench at the bedside – with each patient and their cancer.
The platforms of Therapeutics Discovery are supported by MD Anderson’s Moon Shots Program®.
Therapeutics Pipeline
We have leveraged our unique approach to discover and advance novel small-molecule, biologic and cell-based therapies to answer unmet needs that will improve the lives of our patients.
Learn more about our pipelineIn the News
Stay up to date on our new collaborations and recent progress.
MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets
MD Anderson and Nexo Therapeutics are collaborating at the earliest stages of drug discovery and development to rapidly advance new cancer therapies against previously undruggable targets.
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement
In April, MD Anderson and Generate:Biomedicines announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.
Our Unique Model
We are a drug development engine built within MD Anderson, taking an approach unlike anywhere else. Our experienced teams work collaboratively across industry-scale research platforms to advance new therapies, and we collaborate with leading biopharmaceutical companies to bring new medicines to patients in need.
Learn more about our approach